Peptides edge back toward legal sale, the unregulated-market warning, GLP-1 lawsuits, and a 23% weight-loss combo.

The big one. The Washington Post reports the Trump administration is drafting plans that would allow the temporary sale of certain previously restricted peptides through compounding pharmacies while federal health officials work out permanent regulations. What is confirmed: the report rests on two anonymous sources, the plan has not been announced, HHS has not commented, and nobody outside government knows which peptides it would cover or when it would start. Nothing is legal today that was not legal last week.

The backdrop explains why this is moving now. In April, the FDA removed 12 peptides from its Category 2 list of substances it considers significant safety risks. On July 24, its compounding advisory committee voted - against the unanimous opposition of FDA staff scientists, who flagged thin human data - to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) for the 503A bulks list. That vote is non-binding and still awaits FDA sign-off, so even those six cannot be legally compounded today. A temporary-sale arrangement would bridge the gap while the formal rulemaking runs.

Why it matters: the direction of travel has flipped from restriction toward managed access. For operators this is a preparation signal, not a green light: audit your sourcing, get your documentation and vendor paper trail in order, and watch three things - the actual announcement and its peptide list, whether access runs through 503A pharmacies with patient-specific prescriptions only, and the FDA's final call on the July six. Until a rule or guidance is published, buying or selling these peptides carries exactly the same risk it did in September.

Source: Washington Post, October 7, 2026

PBS NewsHour reports that despite recent price improvements, millions of Americans still cannot afford GLP-1s - and many are turning to cheaper, unregulated versions bought outside the pharmacy channel. The gray market that regulators are trying to close is being sustained by the price gap itself.

Why it matters: price-sensitive demand does not disappear when one channel closes - it moves. For legitimate practices, this is both the competitive opening (a documented, compliant supply chain is a real differentiator right now) and the liability line: patients and vendors arriving from the unregulated market may bring product of unknown identity, purity or potency.

Source: PBS NewsHour, October 6, 2026

NPR examines the two consolidated lawsuits alleging life-altering harm from GLP-1 drugs - including claims that semaglutide caused NAION, a form of sudden vision loss - and the thin data both sides are working with. More than one in 10 Americans are currently taking a GLP-1, per Gallup, and one in seven has taken one at some point, yet rare serious adverse events remain hard to quantify. Novo Nordisk points to subsequent research casting doubt on the NAION link.

Why it matters: with usage this broad, informed-consent conversations and documented counseling on rare risks are becoming standard-of-care territory, not optional extras. Expect plaintiff-side advertising to make your patients ask - have a straight answer ready.

Source: NPR, October 10, 2026

Eli Lilly's 48-week Phase 2b trial paired tirzepatide with eloralintide, an experimental amylin mimic, in 367 adults with obesity and type 2 diabetes. At the highest combination dose, participants lost an average of 23.3% of body weight versus 14.8% on tirzepatide alone, with HbA1c down 2.9% - at the cost of more gastrointestinal side effects. The triple-pathway approach (GLP-1 + GIP + amylin) is shaping up as the next efficacy tier.

Why it matters: the efficacy bar keeps moving. Practices building programs around today's molecules should expect patient expectations - and manufacturer pricing - to be set against results like these within a few years.

Source: New Atlas, October 9, 2026